Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in streptogramin research.

J C Barrière1, N Berthaud, D Beyer

  • 1Rhône-Poulenc Rorer-Centre de Recherche, Vitry-sur-Seine, France.

Current Pharmaceutical Design
|April 10, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ear type in sheep is associated with the MSRB3 locus.

Animal genetics·2020
Same author

A de novo germline mutation of KIT in a white-spotted Brown Swiss cow.

Animal genetics·2020
Same author

Identification of two TYRP1 loss-of-function alleles in Valais Red sheep.

Animal genetics·2019
Same author

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.

Leukemia·2017
Same author

Coinfection of sheep with Anaplasma, Theileria and Babesia species in the Kurdistan Region, Iraq.

Transboundary and emerging diseases·2014
Same author

Identification and partial characterization of a Salp15 homolog from Ixodes ricinus.

Ticks and tick-borne diseases·2014
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Streptogramin antibiotics, including quinupristin/dalfopristin, show potent activity against resistant bacteria by inhibiting protein synthesis. Their synergistic action enhances efficacy, offering a promising treatment for challenging infections.

Area of Science:

  • Microbiology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Streptogramins are natural antibiotics with unique antibacterial mechanisms but limited water solubility.
  • Semisynthetic derivatives like quinupristin/dalfopristin enhance solubility and therapeutic potential.
  • Resistant bacterial infections necessitate novel and effective antibiotic treatments.

Purpose of the Study:

  • To describe the structure and mechanism of action of streptogramin antibiotics.
  • To highlight the development and advantages of semisynthetic streptogramins, such as quinupristin/dalfopristin.
  • To discuss bacterial resistance mechanisms against streptogramins.

Main Methods:

  • Chemical modifications of natural streptogramins (group A and B) to create water-soluble derivatives.

Related Experiment Videos

  • Industrial-scale production of modified streptogramins.
  • Investigation of streptogramin binding to the bacterial ribosome and inhibition of protein synthesis.
  • Analysis of synergistic effects between group A and group B compounds.
  • Characterization of bacterial resistance mechanisms, including ribosomal modification, enzyme inactivation, and efflux.

    • Main Results:

    • Quinupristin/dalfopristin demonstrates potent activity against resistant bacteria like Streptococcus pneumoniae, Staphylococcus aureus, and Enterococcus faecium.
    • Synergistic action between group A and B components enhances antibacterial potency, often resulting in bactericidal effects.
    • Bacterial resistance mechanisms involve ribosomal modification (e.g., MLSB resistance), enzymatic inactivation, and efflux pumps.
    • Semisynthetic streptogramins are produced at an industrial scale, with mutasynthesis enabling production of specific components.

    Conclusions:

    • Semisynthetic streptogramins, particularly quinupristin/dalfopristin, are valuable agents against multidrug-resistant bacteria.
    • The unique synergistic mechanism of streptogramins contributes to their potent and broad-spectrum activity.
    • Understanding resistance mechanisms is crucial for developing strategies to overcome them and preserve the efficacy of streptogramins.